Prof. Dr. Martin Früh
Stv. Chefarzt
Leitung Fachbereich Onkologie
Medizinische Onkologie und Hämatologie · Dept. I
Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland
Jürgens V, ess s, Phuleria H, Früh M, Schwenkglenks M, Frick H, Cerny T, Vounatsou P. Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland. Geospat Health 2013; 7:219-36.
01.05.2013Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland
01.05.2013Geospat Health 2013; 7:219-36
Jürgens Verena, ess silvia, Phuleria Harish C, Früh Martin, Schwenkglenks Matthias, Frick Harald, Cerny Thomas, Vounatsou Penelope
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
Früh M, Pless M, Fustier P, Küttel E, Simcock M, Rauch D, Krasniqi F, Erdmann A, Mamot C, Zippelius A, Tscherry G, Siano M, Cathomas R, Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.
24.05.2012Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
24.05.2012Clin Lung Cancer 2012; 14:34-9
Früh Martin, Pless Miklos, Fustier Pierre, Küttel Erika, Simcock Mathew, Rauch Daniel, Krasniqi Fatima, Erdmann Andreas, Mamot Christoph, Zippelius Alfred, Tscherry Gregor, Siano Marco, Cathomas Richard, Swiss Group for Clinical Cancer Research
Non-Gated F-18 FDG PET/CT For Target Volume Delineation in Stereotactic Body Radiation Therapy (SBRT) in Patients with Malignant Lung Lesions and Clinical Outcome
Klass N, Aebersold D, Krause T, Plasswilm L, Blumstein N, Born E, Cihoric N, Schmidhalter D, Früh M, Malthaner M, Toepfer M, Klaeser B, Schmuecking M (2012). Non-Gated F-18 FDG PET/CT For Target Volume Delineation in Stereotactic Body Radiation Therapy (SBRT) in Patients with Malignant Lung Lesions and Clinical Outcome.
19.04.2012Non-Gated F-18 FDG PET/CT For Target Volume Delineation in Stereotactic Body Radiation Therapy (SBRT) in Patients with Malignant Lung Lesions and Clinical Outcome
19.04.2012SASRO 2012
Klass ND, Aebersold D, Krause T, Plasswilm Ludwig, Blumstein N, Born E, Cihoric N, Schmidhalter D, Früh Martin, Malthaner M, Toepfer Michael, Klaeser B, Schmuecking M
Targeted therapy in non-small cell lung cancer
Putora P, Schneider T, Rodriguez R, Früh M. Targeted therapy in non-small cell lung cancer. Breathe 2012; 8:206-215.
16.03.2012Targeted therapy in non-small cell lung cancer
16.03.2012Breathe 2012; 8:206-215
Putora Paul Martin, Schneider Tino, Rodriguez Regulo, Früh Martin
Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
Hochstrasser A, Benz G, Jörger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
23.02.2012Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
23.02.2012Chemotherapy 2012; 58:84-88
Hochstrasser Andreas, Benz Gabriel, Jörger Markus, Templeton Arnoud, Brutsche Martin, Früh Martin
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
04.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
04.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
Jörger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Ann Oncol 2012; 22:567-574.
01.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
01.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin
Carboplatin- or Cisplatin-based chemotherapy in first-line treatement of scmall cell lung cancer: The COCIS individual patient data meta-analysis
Rossi A, Martelli O, Gridelli C, Gallo C, Perrone F, Shibata T, Samantas E, Tamura T, Qian W, Früh M, Skarlos D, Okamoto H, Rudd R, Chiodini P, Di Maio M, Lee S. Carboplatin- or Cisplatin-based chemotherapy in first-line treatement of scmall cell lung cancer: The COCIS individual patient data meta-analysis. J Clin Oncol 2012:1692-1698.
01.01.2012Carboplatin- or Cisplatin-based chemotherapy in first-line treatement of scmall cell lung cancer: The COCIS individual patient data meta-analysis
01.01.2012J Clin Oncol 2012:1692-1698
Rossi A, Martelli O, Gridelli C, Gallo C, Perrone F, Shibata T, Samantas E, Tamura T, Qian W, Früh Martin, Skarlos DM, Okamoto H, Rudd R, Chiodini P, Di Maio M, Lee SM
The place of radiotherapy in the palliative management of NSCLC
Putora P, Früh M. The place of radiotherapy in the palliative management of NSCLC. Breathe 2011; 8: 134-143 2011
01.12.2011The place of radiotherapy in the palliative management of NSCLC
01.12.2011Breathe 2011; 8: 134-143 2011
Putora Paul Martin, Früh Martin
Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature
Bastian S, Clerici T, Neuweiler J, Cerny T, Früh M. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. Onkologie 2011; 34:665-70.
21.11.2011Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature
21.11.2011Onkologie 2011; 34:665-70
Bastian Sara, Clerici Thomas, Neuweiler Jörg, Cerny Thomas, Früh Martin
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer
Putora P, Benz G, Rodriguez R, Brutsche M, Früh M. Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer. Eur Respir J. 2011; 38:1228-30.
01.11.2011Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer
01.11.2011Eur Respir J. 2011; 38:1228-30
Putora Paul Martin, Benz Gabriel, Rodriguez Regulo, Brutsche Martin, Früh Martin
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer
Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus P, Sorensen J, Felix E, Panel members. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011; 22:1973-1980.
01.09.20111st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer
01.09.2011Ann Oncol 2011; 22:1973-1980
Stahel R, Thatcher N, Früh Martin, Le Péchoux C, Postmus P E, Sorensen J B, Felix E, Panel members
Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience
Früh M, Kacsir B, ess s, Cerny T, Rodriguez R, Plasswilm L. Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol 2011; 187:561-7.
27.06.2011Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience
27.06.2011Strahlenther Onkol 2011; 187:561-7
Früh Martin, Kacsir Bela, ess silvia, Cerny Thomas, Rodriguez Regulo, Plasswilm Ludwig
The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Früh M. The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. Lung Cancer 2011; 72:265-270.
01.06.2011The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
01.06.2011Lung Cancer 2011; 72:265-270
Früh Martin
Advances in Personalized Cancer Management
Früh M, Baty F, Putora P, Brutsche M. Advances in Personalized Cancer Management. In: Advances in Personalized Cancer Management. NovemberLondon: Future Medicine Ltd, 2010. ISBN 978-1-78084-068-0. S. 58-67.
01.01.2011Advances in Personalized Cancer Management
01.01.2011Future Medicine Ltd, ISBN 978-1-78084-068-0
Früh Martin, Baty Florent, Putora Paul Martin, Brutsche Martin
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
13.09.2010Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
13.09.2010Ann Oncol 2010; 22:567-74
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Adjuvant Cisplatin-Based Chemotherapy for Elderly
Früh M, Shepherd F. Adjuvant Cisplatin-Based Chemotherapy for Elderly. EUROPEAN JOURNAL OF CLINICAL & MEDICAL ONCOLOGY 2010:59-63.
06.06.2010Adjuvant Cisplatin-Based Chemotherapy for Elderly
06.06.2010EUROPEAN JOURNAL OF CLINICAL & MEDICAL ONCOLOGY 2010:59-63
Früh Martin, Shepherd Frances
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v116-9.
01.05.2010Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
01.05.2010Ann Oncol 2010; 21 Suppl 5:v116-9
D'Addario G, Früh Martin, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
Jörger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
01.01.2010The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
01.01.2010Current drug targets 2010; 11:37-47
Jörger Markus, Omlin Aurelius, Cerny Thomas, Früh Martin
Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:
Cerny D, Cerny T, ess s, D'Addario G, Früh M. Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:. Onkologie 2009; 32:569-73.
13.10.2009Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:
13.10.2009Onkologie 2009; 32:569-73
Cerny David, Cerny Thomas, ess silvia, D'Addario G, Früh Martin